{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:27:03Z","timestamp":1795026423754,"version":"4.10.2"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>ABSTRACT:<\/jats:title>\n                  <jats:p>Phenylalanine hydroxylase (PAH) deficiency is an autosomal recessive disorder of phenylalanine metabolism that is characterized by insufficient activity of PAH, a hepatic enzyme. Throughout this document, PAH deficiency is used instead of the older nomenclature of phenylketonuria, in order to reflect the spectrum of PAH deficiency and in accordance with the terminology established by the American College of Medical Genetics and Genomics. Aspects of PAH deficiency management that are particularly relevant to obstetrician\u2013gynecologists or other obstetric care providers include the prevention of embryopathy associated with maternal hyperphenylalaninemia and PAH deficiency and the risk of genetic transmission of PAH deficiency. Family planning and prepregnancy counseling are recommended for all reproductive-aged women with PAH deficiency. The fetal brain and heart are particularly vulnerable to high maternal concentrations of phenylalanine. The crucial role played by maternal dietary restriction before and during pregnancy should be stressed in counseling patients with PAH deficiency; the goal should be to normalize blood phenylalanine levels (less than 6 mg\/dL) for at least 3 months before becoming pregnant and to maintain at 2\u20136 mg\/dL during pregnancy, in order to optimize developmental outcomes for the fetus. Although phenylalanine levels are increased in the breast milk of patients with PAH deficiency, breastfed infants who do not have PAH deficiency have normal enzyme levels and no dietary restriction. Breastfeeding is safe for infants born to women who have PAH deficiency provided the infants do not have PAH deficiency. Coordinated medical and nutritional care, as well as follow-up with the patient\u2019s metabolic geneticist or specialist, are important in the postpartum period. Because newborns with PAH deficiency appear normal at birth and early detection can improve developmental outcomes for children, newborn screening for PAH deficiency is mandated in all states. This Committee Opinion has been revised to include updates on advances in the understanding and management of women with PAH deficiency and recommendations on prepregnancy counseling, serial fetal growth assessments, and fetal echocardiography.<\/jats:p>","DOI":"10.1097\/aog.0000000000003768","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T18:54:22Z","timestamp":1585248862000},"page":"e167-e170","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Management of Women With Phenylalanine Hydroxylase Deficiency (Phenylketonuria)"],"prefix":"10.1097","volume":"135","member":"276","reference":[{"key":"R1-20261118","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/gim.2013.157","article-title":"Phenylalanine hydroxylase deficiency: diagnosis and management guideline. American College of Medical Genetics and Genomics Therapeutics Committee [published erratum appears in Genet Med 2014;16:356]","volume":"16","author":"Vockley","year":"2014","journal-title":"Genet Med"},{"key":"R2-20261118","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/00125817-200203000-00006","article-title":"Barriers to successful dietary control among pregnant women with phenylketonuria","volume":"4","author":"Brown","year":"2002","journal-title":"Genet Med"},{"key":"R3-20261118","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1651-2227.2002.tb02852.x","article-title":"New approach to osteopenia in phenylketonuric patients","volume":"91","author":"Perez-Duenas","year":"2002","journal-title":"Acta Paediatr"},{"key":"R4-20261118","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1542\/peds.2008-1485","article-title":"Maternal phenylketonuria. Committee on Genetics","volume":"122","year":"2008","journal-title":"Pediatrics"},{"key":"R5-20261118","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM198011203032104","article-title":"Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies","volume":"303","author":"Lenke","year":"1980","journal-title":"N Engl J Med"},{"key":"R6-20261118","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1542\/peds.112.S4.1537","article-title":"Relation of prenatal phenylalanine exposure to infant and childhood cognitive outcomes: results from the International Maternal PKU Collaborative Study","volume":"112","author":"Widaman","year":"2003","journal-title":"Pediatrics"},{"key":"R7-20261118","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10545-012-9491-0","article-title":"Maternal phenylketonuria: low phenylalaninemia might increase the risk of intra uterine growth retardation. AFDPHE (Association Fran\u00e7aise pour le D\u00e9pistage et la Pr\u00e9vention des Handicaps de l\u2019Enfant)","volume":"35","author":"Teissier","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"R8-20261118","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ymgme.2014.02.013","article-title":"Phenylketonuria Scientific Review Conference: state of the science and future research needs","volume":"112","author":"Camp","year":"2014","journal-title":"Mol Genet Metab"},{"key":"R10-20261118","doi-asserted-by":"crossref","first-page":"F24","DOI":"10.1136\/archdischild-2017-313929","article-title":"Non-invasive prenatal testing of pregnancies at risk for phenylketonuria","volume":"104","author":"Duan","year":"2019","journal-title":"Arch Dis Child Fetal Neonatal Ed"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000003768","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:03:45Z","timestamp":1795025025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000003768"}},"subtitle":["ACOG Committee Opinion, Number 802"],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000003768","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}